C3 glomerulopathy (C3G) is a group of rare kidney diseases characterized by complement dysregulation and predominant C3 deposition in the kidney tissue.
Researchers from Kira Pharmaceuticals LLC and University of Pennsylvania have developed a novel mouse model of rapidly progressing lethal C3 glomerulopathy (C3G), with the aim of assessing whether inhibition of proximal alternative pathway (AP) complement components such as factor D (FD) may be more efficacious than C5 inhibition for the treatment of C3G.
RSS
